Design of Topical Ocular Ciprofloxacin Nanoemulsion for the Management of Bacterial Keratitis
Bacterial keratitis (BK) is a critical ocular infection that can lead to serious visual disability. Ciprofloxacin (CIP), moxifloxacin (MOX), and levofloxacin (LFX) have been accepted as monotherapies by the US Food and Drug Administration for BK treatment. CIP is available commercially at 0.3% <i>w<...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2021-03-01
|
| Rangatū: | Pharmaceuticals |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/1424-8247/14/3/210 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|